Pfizer (PFE) is to develop weight-loss drugs, WSJ reports

Pfizer's move to develop weight-loss drugs signals a strategic pivot that could tap into the growing demand in the obesity treatment space.

Newsquawk StaffPublished On the live feed at 8 more headlines followed before this page went public
Newsquawk headlinesUTC

Arista Networks Inc. (ANET) Q1 2026 (USD): Adj. EPS 0.87 (exp. 0.81), Revenue 2.709bln (exp. 2.62bln), Q2 adj. EPS view 0.88 (exp. 0.86), revenue view 2.8bln (exp. 2.78bln).

Lumentum Holdings (LITE) Q3 2026 (USD): EPS 2.37 (exp. 2.27), Revenue 808mln (exp. 810mln)

Pfizer (PFE) is to develop weight-loss drugs, WSJ reports

UKMTO says it has received a report of an incident within the Strait of Hormuz and verified source reported a cargo vessel hit by unknown projectile

Amazon (AMZN) announces plans to invest more than EUR 15bln in France, creating more than 7,000 permanent jobs

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This initiative may enhance their product portfolio, potentially driving future revenue growth, and could recalibrate market perceptions of Pfizer's capabilities beyond traditional pharmaceuticals. Stakeholder sentiment will likely hinge on the drug development's success and timelines, influencing their equity valuation and competitive positioning in the market.

Related headlines

The whole workspace, free to try.

Try it free